POST LEONARD E 4

What Happened

• Leonard E. Post, a director of CG Oncology (CGON), exercised stock options and sold shares on June 4, 2026. The Form 4 shows he exercised 1,000 shares at $0.60 (cost $600) and immediately sold 1,000 common shares in the open market for $54.50 each (gross proceeds $54,500). Net proceeds from that exercise+sale are approximately $53,900.
• The filing also reports a separate 1,000-share derivative disposition at $0.00 and the acquisition of 9,354 derivative shares at $0.00. The Form does not provide additional detail about the $0.00 disposition or the nature of the 9,354-share award beyond the entries shown.

Key Details

• Transaction date: June 4, 2026; Form filed June 5, 2026 (appears timely).
• Sale: 1,000 shares sold at $54.50 each — gross proceeds $54,500.
• Exercise: 1,000 options exercised at $0.60 each — cost $600.
• Additional derivative entries: 1,000-share disposition at $0.00; 9,354-share award/acquisition at $0.00.
• Shares owned after the transactions: Not specified in the provided report.
• Notable footnotes:
  • F1: The option exercise and sale were executed under a Rule 10b5-1 trading plan adopted March 5, 2026.
  • F2: Indicates certain securities were fully vested.
  • F3: Describes a vesting schedule (1/12 monthly beginning June 4, 2026) for a grant — likely tied to the awarded/derivative shares.

Context

• This was an option exercise followed by an immediate open-market sale (a common cashing-out of exercised options). The 10b5-1 plan note indicates the timing of the sale was pre-planned.
• The additional $0.00 derivative entries (one disposed, one acquired) are recorded on the Form 4 but are not explained in detail; such entries can reflect awards, conversions, or internal share-settlements. The filing is factual and does not state the insider’s motivation.